Navigation Links
Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
Date:3/11/2008

ion of insulin-like growth factor-I (IGF-I) following a single intracoronary administration in an acute care setting after percutaneous coronary intervention to restore blood flow in heart attack patients. Numerous studies have shown that ongoing damage to cells within the infarct zone continues to occur even after blood flow has been restored, a phenomenon known as reperfusion injury. Corgentin is intended to enhance myocardial healing in and around the infarct zone when used as an adjunct to existing pharmacologic and interventional therapies. Results of the study indicate that non-surgical intracoronary infusion of an adenovector carrying a reporter gene to the heart enables robust protein expression in the area of the myocardium at risk due to ischemia and reperfusion injury. The recently completed preclinical development study follows an earlier pilot study using a similar myocardial infarct model in which intracoronary administration of Ad5IGF-I was found to preserve heart tissue and function following an acute myocardial infarction.

"These positive preclinical results confirm that our intracoronary infusion approach can be used to successfully deliver therapeutic adenovectors into acutely ischemic myocardium such as occurs after a heart attack, at very high efficiency, without the need for any needle injections into the myocardium. Confirmation that non-surgical adenovector delivery through a standard catheter such as those used routinely for angiography can effectively target the acutely diseased heart substantially advances our Corgentin development program," stated Christopher J. Reinhard, Chairman and CEO of Cardium. "The highly effective delivery to acutely ischemic myocardium following intracoronary infusion extends the findings of high first pass uptake of Generx in the hearts of patients with chronic ischemia as observed in the AGENT-1 clinical study, and underscores the potential of these approaches to be applied to the treatment of various fo
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... Israel, April 7 InSightec Ltd. announced,today that the ... for the company,s ExAblate(R) 2000 MR-guided Focused Ultrasound,(MRgFUS) system ... Under the new labeling, the agency allows,physicians to treat ... previous,restriction to only treat up to half the fibroid ...
... -- China Sky One,Medical, Inc. ("China Sky One ... ), a,leading fully integrated pharmaceutical company producing,over-the-counter drugs ... that an extension notification filed with the Securities ... 10-K on March 31, 2009, is,related to a ...
... Filtration and Separations Society (AFS) will be holding its 22nd ... Minnesota. , ... Minneapolis, MN (PRWEB) April 7, 2009 ... be holding its 22nd Annual Conference, May 4-7, 2009 at the ...
Cached Biology Technology:FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3China Sky One Medical, Inc. Provides Update on Filing Form 10-K 2China Sky One Medical, Inc. Provides Update on Filing Form 10-K 3University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... UCLA and a team of enterprising UCLA scientists envisioning a ... In 1996, a unique collaboration of leading UCLA scientists ... Inc. and the company now stands to reap $537 ... one of the largest Los Angeles-based private biotech firms poised ...
... gallons of hazardous waste resulting from the nations nuclear ... Washington state called Hanford. Beneath this desert landscape ... thousands of tons of chemicals are captured within the ... subsurface flow paths. These paths create uncertainties about ...
... making, Birds of Peru describes the birds of Peru ... in color, and concise descriptive text. The first two ... Douglas Stotz, PhD, are conservation ecologists and ornithologists in ... Museum will host a free public event launching the ...
Cached Biology News:Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 2Biotech Co. founded by UCLA Scientists to be acquired by Astellas, Pharma Inc. 3Where does stored nuclear waste go? 2Lavishly illustrated guide to Peru's birds describes 1,800 species 2
...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
Biology Products: